About Molecular NeuroImaging
Molecular NeuroImaging is a Healthcare company based in New Haven (United States) founded in 2000, and was acquired by Invicro in February 2016. Company offering specialized imaging services for neurodegenerative and neuropsychiatric disorders. The company has 161 employees. Molecular NeuroImaging offers products and services including Imaging Core Lab, Clinical Adjudication, eClinical, and Preclinical Imaging. Its focus areas include Biopharma Outsourcing, CRO, Diversified and Bioanalytical Services. Its legal entity is MOLECULAR NEUROIMAGING LLC. Its competitors include Bio Rad, Thermo Fisher Scientific and Quanterix; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 2000 and based in New Haven, United States, Molecular NeuroImaging operates in the neuroimaging sector, focusing on PET and SPECT biomarkers for drug development and clinical research in neurodegenerative and neuropsychiatric disorders. Services include radioligand development, manufacturing, imaging study design for Phases 1-4 trials, multi-site coordination, and quantitative image analysis. Expertise covers 22 CNS targets and conditions such as Alzheimers disease, Parkinsons disease, and multiple sclerosis.
- Headquarters New Haven, United States
- Employees 161
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website mnimaging.com
- Social LinkedIn
- Acquired by Invicro (Feb 2016)
- Legal Name Molecular Neuroimaging Llc
Products & Services of Molecular NeuroImaging
Molecular NeuroImaging offers a comprehensive portfolio of products and services, including Imaging Core Lab, Clinical Adjudication, eClinical, and Preclinical Imaging.
Provides high-quality imaging data for global clinical trials
Independent review of trial event assessments for accuracy
Offers randomization and supply management solutions
Supports study designs in pharmaceutical R&D processes
Funding Insights of Molecular NeuroImaging
- Total Rounds 5
- Last Round Grant — $3.04M
- First Round $3.04M
(Jul 2007)
- Investors Count 2
All 5 funding rounds of Molecular NeuroImaging with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Molecular NeuroImaging
Molecular NeuroImaging has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Invicro and OSTI.GOV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Scientific and technical information is managed and disseminated by OSTI.GOV. | osti.gov | Oak Ridge, United States | ||
Provide contract research imaging services and software | 2008 | invicro.com | Boston, United States |
Investor details for Molecular NeuroImaging
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Molecular NeuroImaging
4 dated milestones of Molecular NeuroImaging across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Molecular NeuroImaging is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Grant, of $3.0M.
- Exit Acquired by Invicro.
Competitors of Molecular NeuroImaging
Molecular NeuroImaging has 3 listed competitors in our database, 1 of them funded. They include Bio Rad, Thermo Fisher Scientific and Quanterix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bio-rad.com | 1952 | Hercules, United States | 10 | Portfolio of products and services for life science research and clinical diagnostic markets | ||
| thermofisher.com | 1956 | Waltham, United States | 75,000 | Electron microscopy services and microanalysis instruments are provided. | ||
| quanterix.com | 2007 | Cambridge, United States | $99.5M | 141 | Assay kits for ultra-sensitive biomarker detection are developed. |
Detailed competitors of Molecular NeuroImaging
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Molecular NeuroImaging (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Molecular NeuroImaging
Molecular NeuroImaging was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Molecular NeuroImaging is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Molecular NeuroImaging has 161 employees.
Founded in 2000 and based in New Haven, United States, Molecular NeuroImaging operates in the neuroimaging sector, focusing on PET and SPECT biomarkers for drug development and clinical research in neurodegenerative and neuropsychiatric disorders. Services include radioligand development, manufacturing, imaging study design for Phases 1-4 trials, multi-site coordination, and quantitative image analysis. Expertise covers 22 CNS targets and conditions such as Alzheimers disease, Parkinsons disease, and multiple sclerosis.
Molecular NeuroImaging's top competitors include Thermo Fisher Scientific, Quanterix and Bio Rad.
Molecular NeuroImaging offers Imaging Core Lab, Clinical Adjudication, eClinical, and Preclinical Imaging.
Molecular NeuroImaging operates through Molecular Neuroimaging Llc.
Yes. Molecular NeuroImaging was acquired by Invicro in February 2016.